Beta-Sitosterol

Beta-sitosterol is well characterised for benign prostatic hyperplasia: a Cochrane meta-analysis (4 RCTs, n=519) demonstrated significant improvement in urinary flow and symptom scores. LDL-lowering effects at 2 g/day are supported by consistent clinical evidence. Its transporter competition mechanism is implicated in the antiretroviral drug interaction (reduces NPC1L1-mediated uptake of certain ARVs). African Potato contains beta-sitosterol at concentrations sufficient to produce clinically meaningful intestinal drug absorption interactions.

beta-Sitosterol is a major phytosterol in Bala contributing to anti-inflammatory and analgesic effects. Animal studies support traditional use for musculoskeletal pain.

Beta-sitosterol is well characterised across many plant sources with consistent evidence for modest LDL cholesterol reduction (approximately 10%) at doses of 2 g/day in meta-analyses. Its contribution from Griffonia at typical seed extract doses is negligible relative to dedicated phytosterol supplements.

A 1999 Cochrane-reviewed meta-analysis of four RCTs (Wilt et al.) confirmed that beta-sitosterol significantly improved urinary symptom scores (standardized mean difference −0.35) and peak urinary flow rates (+3.91 mL/sec) versus placebo in BPH patients. Individual studies reported reductions in IPSS of approximately 4–7 points over 6–12 weeks. The Scandinavian Prostate Health Group (SPHG) also documented meaningful reductions in post-void residual volume. Beta-sitosterol's 5-alpha reductase inhibition has been confirmed in cell-free enzyme assays with IC50 values in the micromolar range.

Most extensively researched compound in Pygeum; multiple human clinical trials demonstrate efficacy for BPH symptoms; well-established safety profile

Beta-sitosterol competitively inhibits 5-alpha reductase, reducing DHT conversion from testosterone. Clinical trials show efficacy for androgenic alopecia and hormonal acne in women at 1-2g daily dosing.